NCT01499160 - Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2014

Study Completion Date

December 31, 2016

Conditions

Breast NeoplasmsEndocrine Breast DiseasesNeoplasm Metastasis

Interventions

DRUG

letrozole

Drug is are to be taken orally. 2.5 mg once daily

DRUG

lapatinib

Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)

DRUG

everolimus

Drug is to be taken orally. 5 mg once daily.

Trial Locations (1)

21201

University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore